Hutchmed gets NMPA approval for ATLED in FGFR2+ intrahepatic cholangiocarcinoma
HUTCHMED announced NMPA approval for ATLED (fanregratinib) for patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
HUTCHMED gets NMPA approval for ATLED in FGFR2 intrahepatic cholangiocarcinoma
Hutchmed announced NMPA approval for ATLED (fanregratinib) for treating FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma patients.